Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T-DM1

- PMLiVE

Nektar hit by breast cancer trial setback

NKTR-102 failed to meet phase III targets

- PMLiVE

NICE gives nod to blood cancer drug Gazyvaro

Roche’s leukaemia drug to be used in combination with chemotherapy

EU flag

New cancer meds and drug extensions top CHMP recommendations

Drugs for rare disease, oncology and diabetes top regulator’s endorsements

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Roche’s Zelboraf combination to receive priority FDA review

US regulator to assess drug's use with cobimetinib for melanoma within six months

- PMLiVE

Merck takes promotional responsibility for Erbitux in Japan

Currently co-promotes the drug withBristol-Myers Squibb

- PMLiVE

Takeda’s lung cancer drug motesanib flunks another trial

Drug was unable to extend progression-free survival in study of 400 patients

Roche Basel Switzerland

Roche taps Qualcomm for remote health monitoring

Builds on collaboration with Novartis on remote trial observation

EISAI

Eisai given early approval for new oncology drug

Japanese firm’s thyroid cancer treatment Lenvimaset to be a blockbuster

Catabasis hires Rick Modi as its chief business officer

Will help the firm develop its flagship Duchenne muscular dystrophy product

Roche Basel Switzerland

Roche acquires cancer biobank firm Signature Diagnostics

Marks Swiss firm's fifth deal this year to expand its molecular diagnostics business

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links